1. Introduction

Cross-border transfer of biospecimens refers to the movement of biological materials from one country to another for scientific research, clinical trials, medical diagnosis, pharmaceutical development, genetic testing, biotechnology research, commercial exploitation or public-health investigations.

Biospecimens include:

Human blood, plasma and serum.

Human tissues, organs and bone marrow.

DNA, RNA and genomic samples.

Embryos, gametes and reproductive materials.

Human cells, stem cells and cell lines.

Microbiological specimens, including bacteria, viruses and pathogens.

Animal biological materials.

Plant genetic resources and biological samples.

Microbiome samples.

Biobank-stored biological materials.

For example, an Indian hospital may collect blood and tumour tissue from a patient and send the specimens to a laboratory in the United States for genomic sequencing. That transaction may involve several independent legal obligations concerning informed consent, research ethics, privacy, export controls, customs, biosafety, intellectual property and restrictions on secondary use.

The central legal principle is that lawful collection of a biospecimen does not automatically authorize its international transfer, processing, storage or commercial exploitation.

Cross-border biospecimen compliance therefore requires coordination between the laws of the country of origin, transit jurisdictions and destination country.

2. Objectives of cross-border biospecimen regulation

The regulatory framework seeks to achieve the following objectives:

Protect the dignity, autonomy and privacy of human donors.

Prevent unauthorized commercial exploitation of biological materials.

Ensure scientifically and ethically justified research.

Prevent the international spread of dangerous pathogens.

Protect Indigenous communities and traditional knowledge.

Regulate genetic-data processing and international disclosure.

Ensure traceability and accountability throughout the specimen lifecycle.

Establish liability when biological materials are transferred unlawfully.

3. Indian legal framework governing cross-border biospecimen transfers

India is particularly important because it has specific administrative arrangements for the international transfer of human biological material.

A. ICMR Guidelines on Exchange of Human Biological Material, 1997

The Government of India issued guidelines through the Ministry of Health and Family Welfare on 19 November 1997.

The guidelines cover:

Organs and parts of organs.

Human cells and tissues.

Blood and blood products.

Gametes and embryos.

Foetal tissues.

Human cell lines.

Biological waste materials capable of biomedical research use.

The guidelines address transfers from India to foreign institutions as well as transfers into Indian institutions.

Important requirements include:

The proposed transfer must have a legitimate biomedical research or diagnostic purpose.

The foreign recipient and qualified investigators should be identified.

The purpose and quantity of material must be justified.

Ethical and institutional approvals must be obtained where applicable.

International research collaborations must follow the relevant governmental clearance procedures.

The transfer should be documented through an appropriate Material Transfer Agreement (MTA).

The guidelines also distinguish individual diagnostic or therapeutic exchanges from research transfers. Individual-case exchanges considered necessary by the treating doctors may be treated differently from research exports.

Government of India+1

B. Health Ministry's Screening Committee (HMSC)

The Health Ministry's Screening Committee, administered through the Department of Health Research and ICMR, examines relevant international collaborative health-research proposals.

International collaboration may involve:

Foreign funding.

Foreign laboratory facilities.

International sample processing.

Genetic sequencing abroad.

Sharing biological specimens with overseas research institutions.

International data management.

The applicable screening route depends on the nature of the institution and project. Other relevant committees include the Screening Committee for Research Proposals (SCRP) and the DBT Screening Committee.

Government of India+1

C. Commercial export of human biological material

A critical distinction exists between research transfers and commercial exports.

India's Department of Health Research operates the Transfer of Human Biological Material (THBM) Portal, through which eligible Indian companies and organisations can seek a No Objection Certificate (NOC) for commercial exports.

The official portal expressly states that it is for commercial exports and does not accept research-purpose export applications.

The ICMR's current guidance also refers to DGFT Notification No. 72/2023 governing commercial exports of human biological samples. Therefore, commercial exports should not be treated as ordinary research transfers.

tbm.icmr.gov.in+2

Official resources:

ICMR – Transfer of Human Biological Material

THBM commercial export portal

ICMR biological material transfer guidelines

D. Material Transfer Agreement (MTA)

An MTA is a contractual instrument governing the transfer and use of biological specimens between institutions.

It should address:

An MTA should not be regarded as a substitute for donor consent, ethics approval or government permission.

E. Biological Diversity Act, 2002

India's Biological Diversity Act regulates access to biological resources and associated knowledge, including applicable access-and-benefit-sharing obligations.

Its application must be assessed carefully because human genetic material is not automatically treated in the same way as biological resources covered by biodiversity legislation.

For non-human biological resources, such as plants, microorganisms and certain animal materials, the Act and its implementing rules may become relevant.

The compliance assessment should consider:

Whether the material falls within the statutory definition of biological resources.

Whether it originates in India.

Whether the proposed activity constitutes regulated access or utilisation.

Whether the recipient or applicant falls within a regulated category.

Whether approval, intimation or benefit-sharing obligations apply.

F. Digital Personal Data Protection and genetic information

Biospecimen transfer frequently involves the transfer of associated personal information, such as:

Donor names and identification numbers.

Clinical histories.

Genetic sequences.

Disease information.

Family histories.

Laboratory results.

Research participant codes.

The legal analysis must distinguish the physical specimen from information derived from it.

A transfer of a blood sample may involve one regulatory framework, while the accompanying identifiable genomic dataset may trigger additional data-protection obligations.

The applicable Indian data-protection provisions, commencement notifications and rules must be checked for the relevant transaction and date.

4. International legal framework

A. Nagoya Protocol on Access and Benefit-Sharing

The Nagoya Protocol is an important international instrument governing access to genetic resources and the fair and equitable sharing of benefits arising from their utilisation.

Its main provisions include:

Article 5 – Benefit sharing

Benefits arising from utilisation of genetic resources must be shared fairly and equitably in accordance with applicable national legislation and mutually agreed terms.

Article 6 – Access to genetic resources

Access may be subject to prior informed consent from the provider country, depending on its domestic access legislation.

Article 7 – Traditional knowledge

Access to traditional knowledge associated with genetic resources must respect applicable community rights and consent requirements.

Article 12 – Traditional knowledge and customary practices

Parties are expected to take account of Indigenous and local communities' customary laws and procedures.

Convention on Biological Diversity+2

An important limitation is that the Nagoya Protocol does not automatically govern every human biospecimen transfer. Its scope concerns genetic resources within the Convention on Biological Diversity framework. Human genetic resources are not treated as ordinary genetic resources under that framework.

B. European Union – GDPR

The General Data Protection Regulation (GDPR) becomes relevant when biospecimen transfers involve personal data within its territorial scope.

Relevant provisions include:

Article 4: Personal data and genetic data definitions.

Article 5: Data-processing principles.

Article 6: Lawfulness of processing.

Article 9: Special-category personal data, including genetic and health data.

Article 13 and 14: Transparency and information obligations.

Article 28: Processor obligations.

Article 32: Security of processing.

Articles 44–49: International transfers of personal data.

An institution cannot assume that anonymising a specimen automatically resolves every GDPR issue. Truly anonymous information falls outside the personal-data definition, but pseudonymised information remains personal data where re-identification remains reasonably possible.

C. United States – biospecimen and pathogen regulation

The United States has several regulatory layers:

Human-subject research protections under the Common Rule, where applicable.

HIPAA requirements where protected health information is involved.

FDA requirements where the specimens are used in regulated clinical investigations or product development.

CDC and USDA import requirements for certain biological materials.

Federal Select Agent Program requirements for regulated pathogens and toxins.

Export-control requirements for controlled biological materials and technology.

The Federal Select Agent Program requires appropriate registration and authorisation for covered transfers and imports. Select-agent exports can also require a Department of Commerce export licence.

Federal Select Agent Program

5. Important judicial decisions and case laws

There is no single universally controlling judgment governing all international biospecimen transfers. Courts have instead developed principles concerning informed consent, specimen ownership, confidentiality, research collaboration, commercial exploitation and unauthorised secondary use.

The following cases are particularly relevant.

Case 1. Moore v. Regents of the University of California (1990)

Landmark biospecimen case

Citation: 51 Cal. 3d 120; 793 P.2d 479 (California Supreme Court, 1990).

Facts:

John Moore was treated for hairy-cell leukaemia. His physician obtained biological materials from him during treatment. Without properly disclosing the physician's research and financial interests, the physician and other researchers used Moore's cells to develop a commercially valuable cell line.

Moore challenged the use of his biological materials.

Legal issues:

Whether a patient retains property rights over removed human tissue.

Whether a physician must disclose research and commercial interests.

Whether the patient's consent covers unrelated research.

Judgment:

The California Supreme Court rejected Moore's conversion claim based on ownership of the removed cells. However, it recognised that the allegations could support claims for breach of fiduciary duty and lack of informed consent.

Principle established:

A patient's lack of proprietary rights over removed tissue does not eliminate the physician's duty to disclose material information when obtaining consent.

Relevance to cross-border biospecimen transfers:

An institution cannot assume that clinical consent automatically permits international research transfers or commercial use. Researchers should disclose relevant research purposes and financial interests before obtaining consent.

Justia Law+1

Case 2. Greenberg v. Miami Children's Hospital Research Institute (2003)

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Facts:

Families affected by Canavan disease supplied blood, tissue, financial support and research information to facilitate the identification of the disease-causing gene.

A researcher subsequently isolated and patented the relevant gene sequence. The hospital sought to commercially exploit the resulting genetic testing technology.

The donors challenged the use and commercialisation of their contributions.

Legal issues:

Whether donors had enforceable rights concerning the research results.

Whether commercial exploitation breached the expectations of the research collaboration.

Whether the researchers were unjustly enriched.

Judgment:

The court dismissed several claims, including conversion and certain informed-consent and fiduciary-duty claims, but allowed the unjust-enrichment claim to proceed.

Principle established:

The circumstances of a research collaboration, including the contributions and expectations of participants, may give rise to enforceable legal claims concerning the benefits derived from donated biological materials.

Relevance:

Where an Indian research institution sends genetic specimens to a foreign pharmaceutical company, the MTA should address patent ownership, licensing, commercialisation, benefit sharing and publication rights.

PubMed+1

Case 3. Washington University v. Catalona (2007)

Citation: 490 F.3d 667 (8th Cir. 2007).

Facts:

Dr William Catalona collected biological samples from patients for prostate cancer research at Washington University.

When he moved to another university, he sought to transfer the collected specimens to his new institution. Washington University opposed the transfer and asserted institutional control over the repository.

Legal issue:

Whether research participants or the individual physician could direct the transfer of specimens held in an institutional biorepository.

Judgment:

The Eighth Circuit upheld Washington University's position that the samples were donations to the university, rather than property owned by the individual researcher or participants in the manner claimed.

Principle established:

Institutional control, donor documentation and the terms of specimen donation are important in determining authority over stored biological materials.

Relevance:

A foreign collaborator cannot automatically acquire unrestricted authority over specimens simply because the samples have been physically delivered to its laboratory.

The original institution should maintain documented authority, transfer conditions and restrictions on onward distribution.

Justia Law

Case 4. Havasupai Tribe v. Arizona Board of Regents (2008)

Citation: 220 Ariz. 214, 204 P.3d 1063 (Ariz. Ct. App. 2008).

Important community-consent case

Facts:

Members of the Havasupai Tribe supplied blood samples for research relating to diabetes.

The samples were subsequently used in research involving other subjects, including schizophrenia and population migration. Members of the community argued that these activities exceeded the purposes for which their samples had been collected.

Legal issues:

Whether biological materials were used beyond the authorised research purpose.

Whether the community's expectations and consent were respected.

Whether the institution could be held accountable for subsequent specimen handling and use.

Judgment:

The Arizona Court of Appeals reversed summary judgments against the plaintiffs on procedural notice-of-claim grounds and remanded the litigation. The case was later settled in 2010, with Arizona State University agreeing to pay $700,000 to 41 tribal members.

Principle established:

Consent for one research purpose should not automatically be treated as consent for unrelated research.

Relevance:

Cross-border transfers involving Indigenous populations, minority communities or culturally significant genetic materials require particular attention to collective interests, community engagement and the scope of consent.

A foreign recipient should not independently expand the research purpose beyond the original authorisation.

Justia Law+2

Case 5. Sidaway v. Board of Governors of the Bethlem Royal Hospital (1985)

Citation: [1985] AC 871 (House of Lords, United Kingdom).

Facts and legal issue:

The litigation concerned a doctor's duty to disclose risks associated with medical treatment and the legal standard governing disclosure.

Principle:

The judgment illustrates the historical development of informed-consent law and the importance of disclosure in medical decision-making.

Relevance:

Although it did not concern international biospecimen transfers, it provides historical context for the disclosure duties relevant to obtaining consent for medical procedures from which research specimens may subsequently be collected.

Its approach must be read alongside later developments in patient autonomy, particularly Montgomery v Lanarkshire Health Board (2015).

Case 6. Montgomery v. Lanarkshire Health Board (2015)

Citation: [2015] UKSC 11.

Facts:

The case concerned the failure to disclose a material risk associated with childbirth and the patient's decision-making rights.

Judgment:

The UK Supreme Court confirmed that doctors must take reasonable care to ensure patients are aware of material risks and reasonable alternatives.

Principle:

Informed consent is based on patient autonomy and material information relevant to the patient's decision.

Relevance:

When a biospecimen is collected through a clinical procedure, the consent process should distinguish between clinical treatment and subsequent research use, particularly where international processing or storage is contemplated.

Case 7. S and Marper v. United Kingdom (2008)

Citation: Application Nos. 30562/04 and 30566/04, European Court of Human Rights, Grand Chamber, 4 December 2008.

Facts:

The case concerned the indefinite retention of fingerprints, cellular samples and DNA profiles of individuals who had not been convicted of an offence.

Judgment:

The European Court of Human Rights found a violation of Article 8 of the European Convention on Human Rights, concerning the right to respect for private and family life.

Principle:

The retention and use of biological materials and genetic information engage important privacy and proportionality considerations.

Relevance:

International specimen transfers must address retention periods, access controls, onward disclosure and deletion or destruction obligations.

The case is especially important when biological materials are retained for purposes beyond the original investigation.

6. Major compliance obligations

A. Informed consent

Informed consent is one of the most important safeguards in biospecimen transfer.

The consent document should clearly explain:

The nature of the specimen being collected.

The country to which it may be transferred.

The identity or category of the foreign recipient.

The research or diagnostic purpose.

Whether genetic sequencing will occur.

Whether the sample will be stored in a foreign biobank.

Whether future research is permitted.

Whether commercial development is contemplated.

Whether data may be shared internationally.

Whether the specimen will be destroyed, returned or retained.

Legal problem: A patient may consent to tumour testing for diagnosis without agreeing to unrelated genetic research or pharmaceutical development.

Consequently, institutions must distinguish clinical consent from research consent and broad future-use consent.

B. Ethical committee approval

Before the international movement of human biospecimens, institutions should establish whether approval is required from:

The Institutional Ethics Committee (IEC).

The Institutional Review Board (IRB).

A national research ethics authority.

Relevant governmental screening committees.

Specialised authorities responsible for human embryos, stem cells or reproductive materials.

The committee should examine the scientific purpose, donor protections, specimen quantities, foreign collaborators and proposed secondary uses.

C. Privacy and confidentiality

Biospecimens can reveal highly sensitive information.

For example, DNA sequencing may reveal:

Hereditary diseases.

Ancestral relationships.

Familial genetic risks.

Carrier status.

Disease predispositions.

Biological relationships between individuals.

Accordingly, institutions should use appropriate safeguards:

Pseudonymisation.

Encryption.

Restricted access.

Secure transfer systems.

Confidentiality agreements.

Re-identification restrictions.

Data-retention schedules.

Breach notification procedures.

Importantly, removing a patient's name does not necessarily make a genomic sample anonymous.

D. Export and import permits

The physical transfer of biospecimens may require separate regulatory clearances.

These can include:

The legal classification depends on the precise material, intended use, destination and applicable national legislation.

E. Customs and transportation compliance

Biological specimens must be packaged and transported in accordance with applicable transport regulations.

Relevant international standards include:

International Air Transport Association (IATA) Dangerous Goods Regulations.

ICAO Technical Instructions.

Applicable WHO guidance on infectious-substance transport.

Applicable national customs requirements.

UN packaging and classification standards.

Specimens should be correctly classified as appropriate, including as Category A or Category B infectious substances where applicable.

The shipping documentation should identify the sender, recipient, contents, applicable classification and required permits.

F. Biosafety and biosecurity

Biospecimen transfers may create public-health risks if infectious materials are improperly handled.

Compliance should include:

Appropriate biosafety risk assessment.

Suitable containment facilities.

Trained personnel.

Secure packaging.

Temperature-controlled transportation where necessary.

Emergency response procedures.

Incident reporting.

Documented receipt and storage.

The regulatory obligations become particularly stringent for controlled pathogens and toxins.

7. Intellectual property and commercial exploitation

Cross-border biospecimen transfers frequently produce commercially valuable research outputs.

Examples include:

Genetic diagnostic tests.

Patented cell lines.

Gene therapy technologies.

Pharmaceutical discoveries.

Biomarker identification.

Personalised medicine platforms.

Artificial intelligence-based genomic databases.

The parties must distinguish between ownership of the original specimen and ownership of inventions or information derived from it.

An MTA should expressly regulate:

1. Background intellectual property: Technology and intellectual property already owned by either institution.

2. Foreground intellectual property: New inventions, methods and discoveries generated through the research.

3. Patent rights: Whether the foreign institution can independently patent discoveries.

4. Licensing rights: Whether commercial use requires approval from the originating institution.

5. Benefit sharing: Whether financial or non-financial benefits must be provided to the originating institution or eligible communities.

6. Publication rights: Whether researchers can publish findings without disclosing confidential donor information.

The principles in Moore and Greenberg demonstrate why commercial interests, donor expectations and the contractual arrangements governing biological materials must be addressed separately.

8. Liability for unlawful cross-border biospecimen transfers

Different forms of legal liability may arise.

A. Liability of the originating institution

The originating institution may be liable where it:

Collects specimens without appropriate consent.

Transfers materials without required clearance.

Misrepresents the research purpose.

Fails to protect donor confidentiality.

Ignores restrictions on onward transfer.

Fails to conduct appropriate due diligence.

B. Liability of the foreign recipient

The foreign recipient may incur liability if it:

Uses specimens beyond the authorised purpose.

Transfers specimens to another institution without permission.

Publishes identifiable genetic information unlawfully.

Conducts unapproved research.

Commercialises specimens contrary to contractual restrictions.

Violates applicable import, biosafety or data-protection laws.

C. Joint institutional liability

Where both institutions participate in unauthorised specimen handling, liability may arise under the applicable contractual, statutory and tort-law frameworks.

An MTA should therefore allocate responsibility for compliance, supervision, insurance, indemnification and dispute resolution.

9. Special compliance issues involving different types of biospecimens

10. Practical compliance procedure for an Indian institution transferring specimens abroad

The following sequence provides a useful compliance model.

Identify and classify the specimen

Determine whether it is human, animal, plant, microbial, infectious, reproductive or genetically modified material.

Establish the legal basis for collection

Verify donor consent, clinical authority, research approval and ownership or custodial authority.

Identify the purpose of transfer

Separate individual diagnosis, collaborative research, clinical trials and commercial exports.

Obtain ethical and governmental approvals

Determine whether IEC, HMSC, SCRP, DBT or other applicable regulatory clearance is required.

Execute an MTA

Specify permitted use, storage, confidentiality, intellectual property, benefit sharing and disposal.

Verify foreign recipient compliance

Confirm its licences, institutional approvals, biosafety capabilities and data-protection arrangements.

Complete export and import formalities

Obtain applicable NOCs, permits, customs documentation and transport authorisations.

Transport securely

Use appropriate packaging, classification, temperature controls and chain-of-custody documentation.

Monitor subsequent use

Conduct audits, monitor secondary research, restrict onward transfers and document specimen destruction or return.

11. Emerging legal challenges

A. Artificial intelligence and genomic specimen transfers

AI-based genomic research creates new challenges because a specimen may generate enormous quantities of sensitive genetic information.

Questions include:

Can a foreign AI company use genomic samples to train commercial models?

Does original consent cover AI training?

Can genomic information be transferred to cloud infrastructure in another country?

Who is responsible for re-identification?

Can AI-generated discoveries be patented?

B. Biobank sovereignty

Biobanks increasingly store biological materials for decades.

This raises questions about:

Institutional control over stored specimens.

National sovereignty over biological resources.

Donor withdrawal rights.

Foreign ownership of biobank infrastructure.

Long-term international access.

Transfer of specimens following institutional closure.

C. Genetic colonialism

Genetic colonialism describes situations in which biological materials and genetic information are collected from communities in developing countries and exploited by institutions in more economically powerful countries without adequate participation or benefit sharing.

The Havasupai litigation illustrates the importance of protecting community interests and respecting the scope of consent.

D. Synthetic biology and cell-line development

Human and microbial biological materials may be transformed into commercially valuable research platforms.

This raises questions about whether original consent permits:

Synthetic cell development.

Genetic modification.

Immortalised cell-line creation.

Commercial manufacturing.

Distribution to third-party laboratories.

E. Cross-border specimen traceability

A major challenge is determining where specimens go after the initial transfer.

A specimen might travel from India to Singapore, then to Germany and finally to a US biotechnology company.

Each transfer may create additional contractual, regulatory, privacy and biosafety obligations.

A robust traceability system should maintain a record of every recipient, transfer date, permitted use, derivative material and disposal event.

12. Important international instruments and legislation

13. Critical legal principles emerging from case law

The principal judicial lessons can be summarised as follows:

These decisions do not establish one uniform international transfer rule. Their significance lies in the legal principles that institutions must apply when designing specimen-transfer arrangements.

14. Critical analysis

Cross-border biospecimen regulation faces a fundamental difficulty: biological specimens are simultaneously physical materials, sources of personal information, scientific resources and potential commercial assets.

Traditional export regulations primarily regulate physical movement. However, modern biotechnology allows biological materials to be digitised, sequenced, replicated and transformed into new research products.

Consequently, a specimen can leave the country physically while its genetic information remains available through international databases indefinitely.

Three regulatory weaknesses are particularly important.

First, fragmentation of regulatory authority. Export permission, ethical approval, data protection and biosafety may be administered by different authorities. Approval under one framework does not automatically satisfy another.

Second, inadequate control over secondary use. Original consent may be interpreted too broadly, resulting in research unrelated to the purpose for which the specimen was collected.

Third, uncertainty concerning commercial benefits. Institutions and donors may disagree about who should benefit from patents, diagnostic products and other commercial developments.

An effective regulatory model should therefore combine donor autonomy, institutional accountability, national regulatory supervision, international cooperation and enforceable contractual controls.

15. Conclusion

Cross-border transfer of biospecimens is a complex area of biotechnology, medical research, international trade, privacy and biosecurity law.

In India, the ICMR framework, the Health Ministry's international research-clearance mechanisms, applicable DGFT requirements and the THBM commercial-export system are particularly important.

Internationally, the Nagoya Protocol, GDPR, applicable US research regulations and pathogen-control frameworks provide additional safeguards, depending on the material and proposed activity.

The most important legal lesson emerging from Moore, Greenberg, Catalona and Havasupai is that physical possession of a biological specimen does not automatically confer unrestricted authority to use, transfer, commercialise or disclose information derived from it.

A legally defensible international transfer requires lawful collection, appropriate consent, regulatory approval, a properly drafted MTA, secure transportation, traceability and continuing oversight.

16. Important research and examination questions

Whether international transfer of human biological materials requires separate donor consent.

Whether an MTA can create enforceable restrictions on foreign research institutions.

Whether a foreign recipient can patent inventions derived from Indian biological specimens.

Whether genetic information can be transferred independently of the physical specimen.

Whether Indigenous communities possess additional rights concerning collective genetic materials.

Whether the Nagoya Protocol applies to human genetic specimens.

Whether institutions are liable for unauthorised secondary use of transferred specimens.

Whether donors can demand destruction or return of specimens already transferred abroad.

Whether commercial biospecimen exports require additional Indian governmental approval.

Whether AI training using internationally transferred genomic specimens constitutes a new research purpose.

Useful primary research sources

ICMR – Guidelines for Exchange of Human Biological Material

ICMR – Transfer of Human Biological Material

Nagoya Protocol – Article 6

Moore v. Regents – Full judgment

Washington University v. Catalona – Full judgment

Havasupai Tribe litigation

Academic qualification: This is a comparative legal research explanation, not a determination that every listed approval is required for every specimen. The exact requirements depend on the specimen's classification, purpose, country of origin, destination, recipient and applicable rules in force on the transfer date.